Postmarketing Surveillance Study of Atrovent® in Chronic Obstructive Airways Disease

Boehringer Ingelheim1,039 enrolled

Overview

Study to obtain further information on the tolerability and efficacy of Atrovent® unit dose vial 500 µg in the treatment of Chronic Obstructive Airways Disease under conditions of daily practice

Study Type

OBSERVATIONAL

Enrollment

1,039

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

Atrovent®DRUG

Eligibility

Sex: ALLMin age: 30 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Primarily patients of both gender, older than 30 years, who suffer from chronic obstructive airways disease * Only patients who had not been treated with Atrovent® within the last year were to be considered for inclusion Exclusion Criteria: * Contraindication listed in the instructions for use/summary of product characteristics for Atrovent® unit dose vial 500 µg

Outcomes

Primary Outcomes

Change in total severity of the clinical picture rated on a 4-point scale

Time frame: after 4 weeks

Secondary Outcomes

Assessment of efficacy by investigator on a 4-point scale

Time frame: after 4 weeks

Assessment of efficacy by patient on a 4-point scale

Time frame: after 4 weeks

Assessment of tolerability by investigator on a 4-point scale

Time frame: after 4 weeks

Assessment of tolerability by patient on a 4-point scale

Time frame: after 4 weeks

Number of patients with adverse drug reactions

Time frame: up to 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.